UPDATE: Credit Suisse Reiterates On BIND Therapeutics After AMGN Declines Option On Accurin Technology
July 03, 2014 at 08:28 AM EDT
In a report published Thursday, Credit Suisse analyst Jason Kantor reiterated an Outperform rating on BIND Therapeutics (NASDAQ: BIND), ...